Published in J Am Acad Child Adolesc Psychiatry on October 01, 2006
Family support in children's mental health: a review and synthesis. Clin Child Fam Psychol Rev (2010) 1.93
Psychiatric diagnosis - is it universal or relative to culture? J Child Psychol Psychiatry (2008) 1.73
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry (2009) 1.55
Cognitive-behavioral therapy for adolescent depression and suicidality. Child Adolesc Psychiatr Clin N Am (2011) 1.14
Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact. J Am Acad Child Adolesc Psychiatry (2011) 1.04
Outcome domains in child mental health research since 1996: have they changed and why does it matter? J Am Acad Child Adolesc Psychiatry (2012) 0.97
Comorbid adolescent substance use and major depressive disorders: a review. Psychiatry (Edgmont) (2007) 0.85
Should young people be given antidepressants? Yes. BMJ (2007) 0.83
Depression in children and adolescents. BMJ Clin Evid (2009) 0.82
Cognitive measures of adolescent depression: unique or unitary constructs? J Clin Child Adolesc Psychol (2009) 0.81
Early patterns of symptom change signal remission with interpersonal psychotherapy for depressed adolescents. Depress Anxiety (2011) 0.81
Enhancing the developmental appropriateness of treatment for depression in youth: integrating the family in treatment. Child Adolesc Psychiatr Clin N Am (2012) 0.80
Improving the transportability of CBT for internalizing disorders in children. Clin Child Fam Psychol Rev (2011) 0.79
Treatment and Prevention of Depression and Anxiety in Youth: Test of Cross-Over Effects. Depress Anxiety (2016) 0.77
Evidence Base Update of Psychosocial Treatments for Child and Adolescent Depression. J Clin Child Adolesc Psychol (2016) 0.77
Do Hospital and Community SSRI Usage Patterns in Children and Adolescents Match the Evidence? J Can Acad Child Adolesc Psychiatry (2010) 0.77
A Pilot SMART for Developing an Adaptive Treatment Strategy for Adolescent Depression. J Clin Child Adolesc Psychol (2015) 0.77
Combined cognitive-behavioural therapy and pharmacotherapy for adolescent depression: Does it improve outcomes compared with monotherapy? CNS Drugs (2009) 0.76
Depression in adolescents. BMJ (2007) 0.76
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial. Trials (2014) 0.75
A systematic review of mental health outcome measures for young people aged 12 to 25 years. BMC Psychiatry (2015) 0.75
Treatment of adolescent depression. Curr Psychiatry Rep (2007) 0.75
The use of cognitive behavioral therapy in the treatment of resistant depression in adolescents. Adolesc Health Med Ther (2012) 0.75
Family support programs and adolescent mental health: review of evidence. Adolesc Health Med Ther (2014) 0.75
Computerised cognitive-behavioural therapy for depression in adolescents: feasibility results and 4-month outcomes of a UK randomised controlled trial. BMJ Open (2017) 0.75
Augmenting Cognitive Behavior Therapy for School Refusal with Fluoxetine: A Randomized Controlled Trial. Child Psychiatry Hum Dev (2017) 0.75
Developmentally sensitive cognitive behavioral therapy for adolescent school refusal: rationale and case illustration. Clin Child Fam Psychol Rev (2014) 0.75
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry (2009) 3.24
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend (2007) 2.22
A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat (2009) 2.03
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Psychopathology in children and adolescents with autism compared to young people with intellectual disability. J Autism Dev Disord (2006) 1.89
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
A Study of Methadone Maintenance For Male Prisoners: 3-Month Postrelease Outcomes. Crim Justice Behav (2008) 1.54
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
Psychopathology in young people with intellectual disability. JAMA (2006) 1.48
Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico. J Addict Med (2007) 1.47
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol (2012) 1.31
Gait function in newly diagnosed children with autism: Cerebellar and basal ganglia related motor disorder. Dev Med Child Neurol (2006) 1.26
The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry (2014) 1.24
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer (2010) 1.24
Alpha-v integrins as therapeutic targets in oncology. Cancer Invest (2007) 1.22
Screening young people for autism with the developmental behavior checklist. J Am Acad Child Adolesc Psychiatry (2002) 1.22
An examination of movement kinematics in young people with high-functioning autism and Asperger's disorder: further evidence for a motor planning deficit. J Autism Dev Disord (2006) 1.16
Using the Autism Diagnostic Interview-Revised and the Autism Diagnostic Observation Schedule with young children with developmental delay: evaluating diagnostic validity. J Autism Dev Disord (2007) 1.15
Factors that predict adolescent motivation for substance abuse treatment. J Subst Abuse Treat (2003) 1.13
Autism and ADHD: how far have we come in the comorbidity debate? Neurosci Biobehav Rev (2010) 1.11
Interim methadone treatment: impact on arrests. Drug Alcohol Depend (2009) 1.09
Developing and Implementing a New Prison-Based Buprenorphine Treatment Program. J Offender Rehabil (2010) 1.07
Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int (2003) 1.06
Gait function in high-functioning autism and Asperger's disorder : evidence for basal-ganglia and cerebellar involvement? Eur Child Adolesc Psychiatry (2006) 1.03
Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime. Subst Abus (2012) 1.03
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res (2004) 1.02
The normative development of emotion regulation strategy use in children and adolescents: a 2-year follow-up study. J Child Psychol Psychiatry (2009) 1.00
Early features of autism: Repetitive behaviours in young children. Eur Child Adolesc Psychiatry (2006) 0.99
GABAergic activity in autism spectrum disorders: an investigation of cortical inhibition via transcranial magnetic stimulation. Neuropharmacology (2012) 0.99
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res (2010) 0.99
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus (2012) 0.97
Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol (2006) 0.97
Evaluation of a group-based substance abuse treatment program for adolescents. J Subst Abuse Treat (2004) 0.96
Differential olfactory identification in children with autism and Asperger's disorder: a comparative and longitudinal study. J Autism Dev Disord (2011) 0.95
Mirror neuron activity associated with social impairments but not age in autism spectrum disorder. Biol Psychiatry (2011) 0.95
Evaluation of child therapy and caregiver training in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry (2002) 0.95
Adult outcomes in autism: community inclusion and living skills. J Autism Dev Disord (2014) 0.94
Lateralization in individuals with high-functioning autism and Asperger's disorder: a frontostriatal model. J Autism Dev Disord (2002) 0.94
A clinical and neurobehavioural review of high-functioning autism and Asperger's disorder. Aust N Z J Psychiatry (2002) 0.93
Gender differences in neurodevelopmental disorders: autism and fragile x syndrome. Curr Top Behav Neurosci (2011) 0.93
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res (2010) 0.91
Factor analytic study of repetitive behaviours in young children with Pervasive Developmental Disorders. J Autism Dev Disord (2009) 0.91
Assessing emotional and behavioral problems in children with intellectual disability: revisiting the factor structure of the developmental behavior checklist. J Autism Dev Disord (2002) 0.90
Differentiation of high-functioning autism and Asperger's disorder based on neuromotor behaviour. J Autism Dev Disord (2012) 0.90
Mortality in Prader-Willi syndrome. Am J Ment Retard (2006) 0.90
A preliminary transcranial magnetic stimulation study of cortical inhibition and excitability in high-functioning autism and Asperger disorder. Dev Med Child Neurol (2010) 0.89
Endoglin for targeted cancer treatment. Curr Oncol Rep (2014) 0.89
Prevention and early intervention for behaviour problems in children with developmental disabilities. Curr Opin Psychiatry (2013) 0.88
Cognitive behavioral therapy age effects in child and adolescent anxiety: an individual patient data metaanalysis. Depress Anxiety (2013) 0.88
Screening for autism in infants and preschool children with developmental delay. Aust N Z J Psychiatry (2005) 0.88
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med (2012) 0.87
Correlated and coupled within-person change in emotional and behavioral disturbance in individuals with intellectual disability. Am J Intellect Dev Disabil (2009) 0.87
Predicting retention of adolescents in substance abuse treatment. Addict Behav (2004) 0.86
Electrophysiological signs of supplementary-motor-area deficits in high-functioning autism but not Asperger syndrome: an examination of internally cued movement-related potentials. Dev Med Child Neurol (2009) 0.85
Bedside cardiology skills training for the osteopathic internist using simulation technology. J Am Osteopath Assoc (2003) 0.84
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer Metastasis Rev (2006) 0.84
The Self-Efficacy Questionnaire for Depression in Adolescents (SEQ-DA). Development and psychometric evaluation. Eur Child Adolesc Psychiatry (2005) 0.84
Cognitive behavior therapy for anxious adolescents: developmental influences on treatment design and delivery. Clin Child Fam Psychol Rev (2009) 0.83
Stroke training of prehospital providers: an example of simulation-enhanced blended learning and evaluation. Med Teach (2005) 0.83
Emotion recognition of static and dynamic faces in autism spectrum disorder. Cogn Emot (2013) 0.83
Movement-related potentials in high-functioning autism and Asperger's disorder. Dev Med Child Neurol (2006) 0.82
Could head circumference be used to screen for autism in young males with developmental delay? J Paediatr Child Health (2011) 0.82
Treatment of children's nighttime fears: the need for a modern randomised controlled trial. Clin Psychol Rev (2006) 0.82
Short form of the developmental behaviour checklist. Am J Ment Retard (2007) 0.82
Repetitive transcranial magnetic stimulation (rTMS) improves movement-related cortical potentials in autism spectrum disorders. Brain Stimul (2011) 0.82
Extracting more information from behaviour checklists by using components of mean based scores. Int J Methods Psychiatr Res (2008) 0.82
The longitudinal relationship between behavior and emotional disturbance in young people with intellectual disability and maternal mental health. Res Dev Disabil (2011) 0.82
Interpersonal motor resonance in autism spectrum disorder: evidence against a global "mirror system" deficit. Front Hum Neurosci (2013) 0.82
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 0.81
Teaching emotion recognition skills to young children with autism: a randomised controlled trial of an emotion training programme. J Child Psychol Psychiatry (2012) 0.81
Evolution of Symptoms and Syndromes of Psychopathology in Young People with Mental Retardation. Int Rev Res Ment Retard (2006) 0.81
Pseudo-random number generation in children with high-functioning autism and Asperger's disorder: further evidence for a dissociation in executive functioning? Autism (2006) 0.80
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res (2011) 0.80
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncol (2013) 0.80
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol (2014) 0.80
A neurobehavioral examination of individuals with high-functioning autism and Asperger's disorder using a fronto-striatal model of dysfunction. Behav Cogn Neurosci Rev (2002) 0.80
Patterns of depressive symptoms and social relating behaviors differ over time from other behavioral domains for young people with Down syndrome. Medicine (Baltimore) (2015) 0.80
Assessing therapy-relevant cognitive capacities in young people: development and psychometric evaluation of the self-reflection and insight scale for youth. Behav Cogn Psychother (2010) 0.79
Skill improvement during emergency response to terrorism training. Prehosp Emerg Care (2006) 0.79
Postprison release HIV-risk behaviors in a randomized trial of methadone treatment for prisoners. Am J Addict (2012) 0.79
Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS. Brain Stimul (2014) 0.79
Effects of the PPAR-gamma agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes. J Renin Angiotensin Aldosterone Syst (2006) 0.78
Development, implementation and outcomes of a training program for responders to acts of terrorism. Prehosp Emerg Care (2006) 0.78
Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematol Oncol Clin North Am (2004) 0.78
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors. J Pharm Sci (2013) 0.78
Explaining labor force status following spinal cord injury: the contribution of psychological variables. J Rehabil Med (2003) 0.78
Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies. Am J Clin Oncol (2002) 0.78
Efficacy of cognitive processes in young people with high-functioning autism spectrum disorder using a novel visual information-processing task. J Autism Dev Disord (2014) 0.78